Efficacy and Safety of Zolpidem Administered ‘As Needed’ in Primary Insomnia
- 120 Downloads
Objective: To assess the efficacy and safety of zolpidem administered on an ‘as needed’ basis for 4 weeks in primary insomnia.
Design: Multicentre, double-blind, randomised, placebo-controlled study.
Setting: 58 primary care centres in France.
Patients and Participants: 245 individuals with primary insomnia.
Methods: Following a placebo run-in period, patients were given four tablets containing either placebo or zolpidem 10mg and were instructed to take one tablet on the first two nights, the two remaining tablets to be taken when required throughout the week. This was followed by a 3-week period during which patients were provided with placebo or zolpidem but advised to use as few tablets as possible.
Results: Premature withdrawals due to inefficacy were significantly more common with placebo than with zolpidem (5% vs 0%; p = 0.01). At the end of the study, total sleep time was increased in both groups, the difference being slightly more marked in the zolpidem group (74.6 vs 63.2 minutes; p = nonsignificant). Zolpidem was significantly (p < 0.05) more effective than placebo with respect to sleep quality, daytime drowsiness, quality of life and Clinical Global Impression scales. Safety was comparable in both groups, as was drug consumption, suggesting a lack of any drug-seeking behaviour.
Conclusion: Zolpidem administered ‘as needed’ is a feasible, well tolerated and promising additional option for the management of primary insomnia.
KeywordsZolpidem Epworth Sleepiness Scale Sleep Onset Total Sleep Time Sleep Diary
The authors gratefully acknowledge the participation of the Zolpidem Study group: P. Beignot Devalmont, E. Bin, B. Bougeard, G. Boulenge, P. Boyer, J.-M. Brasser, C. Burguier, A. Campagne, J. Castellani, C. Cazes, P. Chapelain, G. Chastan, P. Chazot, F. Chopart, L. Choteau, I. Compagnon, J.-J. Crappier, M.-C. Dalle-Rive, J. David, G. Delamare, G. Duffaut, M. Duret-Rolland, N. Ecochard Cirica, R. Eoche, J.-M. Euvrard, G. Faugas, A. Fortis, D. Frenehard, J.-L. Gabrielli, M.-E. Garros, B. Gautier, R. Gaveau, G. Girardier, V. Guinot, G. Guist’Hau, M. Herne, P. Jallon, O. Jousset, C. Lannier, A. Le Guhennec, J. Lefrançois, J.-F. Massiani, D. Meker, P. Montandrau, G.M. Paillard, J. Peluau, A. Ponsot, M. Pozo, H. Pradere, M. Ripoli, J.-M. Roi, P. Sébastien, J.-P. Sentenac, J.-J. Simon, H.-W. Speiss, L. Talazac, H. Traverson, J.-M. Vrinat.
The authors would also like to thank the medical team of Sanofi-Synthélabo: C. Lassale MD, J. Lavoisy MD, C. Soubrane MD and A. Stalla-Bourdillon MD. The study was supported by Sanofi-Synthelabo.
- 3.National Sleep Foundation. Sleep in America: a national survey of US adults. Princeton (NJ): The Gallup Organisations, 1995Google Scholar
- 5.Morin CM. Insomnia: psychological assessment and management. New York: Guildford Press, 1993Google Scholar
- 9.Roth T, Puech A, Paiva T. Zolpidem —place in therapy. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996: 215–30Google Scholar
- 14.Fraisse J, Garrigou-Gadenne D, Thénot JP. Pharmacokinetic and metabolic profiles of zolpidem. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996: 45–58Google Scholar
- 15.Vogel G, Thumond A, Macintosh M, et al. The effect of zolpidem on transient insomnia. Sleep Res 1988; 17: 67Google Scholar
- 18.Vogel G, Scharf M, Walsh J, et al. Effects of chronically administered zolpidem on the sleep of healthy insomniacs. Sleep Res 1989; 18: 80Google Scholar
- 19.Lahmeyer H, Doherty J, Fillingim J, et al. The effect of zolpidem in outpatients with chronic insomnia. Sleep Res 1990; 19: 70Google Scholar
- 24.Costa E, Silva JA, Chase M, et al. Special report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: an overview of insomnias and related disorders-recognition, epidemiology and rational management. Sleep 1996; 19(5): 412–6Google Scholar
- 25.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association, 1994Google Scholar
- 29.Guy W. ECDEU Assessment manual for psychopharmacology, revised 1976. Rockville (MD): National Institute of Mental Health, Psychopharmacology Research Branch, 1976; 53: 217–22,313-31Google Scholar
- 30.Ware JE. SF-36 health survey. Manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center, 1993Google Scholar
- 31.Stewart AL, Ware JE, editors. Measuring functioning and well-being. The Medical Outcomes Study approach. Durham and London: Duke University Press, 1992Google Scholar
- 35.Walsh JK, Roth T, Jamieson A, et al. Intermittent use of zolpidem for the treatment of primary insomnia. Sleep 2000; 23Suppl. 2: A86Google Scholar